Initiator Pharma A/S (SE:INIT)
:INIT
Want to see SE:INIT full AI Analyst Report?
Top Page
Initiator Pharma A/S
(INIT)
Select Model
Select Model
Rating:42Neutral
Price Target:
kr3.00
▼(-1.32% Downside)
Action:Reiterated
Date:05/16/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and sustained cash burn that implies continued external funding needs despite modest leverage). Technical indicators add a secondary headwind with a generally weak trend (below key moving averages and negative MACD). Valuation is difficult to support on earnings due to a negative P/E and no dividend yield provided.
Positive Factors
Focused clinical pipeline
A concentrated pipeline in sexual and reproductive health with small-molecule candidates signals strategic focus and domain expertise. That specialization can improve R&D efficiency, foster regulatory know-how, and make assets more attractive to partners for late-stage development and commercialization over the coming months.
Negative Factors
Pre-revenue with widening losses
The company remains pre-revenue with materially widening losses year-over-year, reflecting sustained R&D and operating spend without commercial offsets. This structural loss profile means ongoing dependence on external financing and creates execution risk if clinical progress or partner deals are delayed.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused clinical pipeline
A concentrated pipeline in sexual and reproductive health with small-molecule candidates signals strategic focus and domain expertise. That specialization can improve R&D efficiency, foster regulatory know-how, and make assets more attractive to partners for late-stage development and commercialization over the coming months.
Read all positive factors
Initiator Pharma A/S (INIT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr204.67M
Dividend YieldN/A
Average Volume (3M)133.41K
Price to Earnings (P/E)―
Beta (1Y)0.60
Revenue GrowthN/A
EPS Growth-58.96%
CountrySE
Employees2
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.33
Shares Outstanding68,452,890
10 Day Avg. Volume157,519
30 Day Avg. Volume133,406
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)4.31
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.31
Revenue Forecast (FY)N/A
Initiator Pharma A/S Business Overview & Revenue Model
Company Description
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. It develops IP2018, a monoamine reuptake inhibitor for the treatment of psychogenic erectil...
How the Company Makes Money
null...
Initiator Pharma A/S Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -12.73M | -14.83M | -11.07K | -23.41K | -38.42K | -21.63K |
| EBITDA | -26.41M | -18.20M | -14.50K | -27.03K | -41.73K | -23.06K |
| Net Income | -22.38M | -14.01M | -12.93K | -22.87K | -38.45M | -21.06M |
Balance Sheet | ||||||
| Total Assets | 26.78M | 32.99M | 15.29M | 29.79M | 48.34M | 53.70M |
| Cash, Cash Equivalents and Short-Term Investments | 19.90M | 26.26M | 13.37M | 24.34M | 38.91M | 34.15M |
| Total Debt | 7.56M | 2.15M | 0.00 | 15.44M | 12.58M | 13.29M |
| Total Liabilities | 8.70M | 3.43M | 510.00K | 18.62M | 14.32M | 18.71M |
| Stockholders Equity | 18.08M | 29.56M | 14.78M | 11.16M | 34.02M | 34.99M |
Cash Flow | ||||||
| Free Cash Flow | -16.26M | 0.00 | -12.08M | -17.65M | -32.70M | -34.10M |
| Operating Cash Flow | -18.46M | -18.19M | -12.08M | -17.65M | -32.70M | -34.10M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -17.00K | 0.00 |
| Financing Cash Flow | 33.55M | 31.36M | 1.11M | 2.87M | 37.48M | 54.94M |
Initiator Pharma A/S Peers Comparison
UnderperformOutperform
Sector (51)
SE:INIT
Initiator Pharma A/S
3.02
-0.87
-22.37%
SE:MVIR
Medivir AB
2.04
0.26
14.33%
DE:5IU
Isofol Medical AB
0.05
-0.03
-40.00%
DE:1XT
Xintela AB
0.01
-0.02
-67.65%
DE:99Z
Modus Therapeutics Holding AB
0.03
-0.02
-39.13%
DE:BTPC
Active Biotech AB
0.01
-0.01
-50.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.